Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention

Clinical trial NCT05844202 · COMPLETED

Trial details

NCT number: NCT05844202
Sponsor: Alvea Holdings, LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Sars-CoV-2 Infection

Start date: 2022-06-27
Primary completion: 2023-03-02
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.